BioXcel Therapeutics Inc. Files for Chapter 11 and Agrees to Asset Sale with Teva Pharmaceuticals
On 28 August 2026, BioXcel Therapeutics Inc. (NASDAQ: BXCL), a commercial‑stage biopharmaceutical company focused on neuroscience and immuno‑oncology, announced that it has entered into a Chapter 11 bankruptcy filing. In connection with the bankruptcy, the company entered into an asset sale agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA).
Key Points of the Transaction
| Item | Detail |
|---|---|
| Asset being sold | BioXcel’s novel dexmedetomidine sublingual film, designated BXCL501, which is under FDA review for at‑home treatment of agitation associated with schizophrenia or bipolar disorders. |
| Bid amount | Teva has submitted a stalking‑horse bid of $57.5 million for the asset. |
| Sale process | The sale is being conducted under court‑supervised proceedings. It is subject to bankruptcy court approval, potential competing bids, and customary closing conditions. |
| Strategic rationale | Teva’s announcement emphasized a disciplined business‑development approach and a pivot toward growth strategy, highlighting the product’s fit with Teva’s portfolio and potential long‑term value. |
| Impact on BioXcel shareholders | The asset sale is part of BioXcel’s restructuring plan following its Chapter 11 filing, intended to liquidate assets and provide liquidity to creditors and shareholders. |
Context and Market Reaction
- BioXcel’s share price fell sharply following the bankruptcy filing, dropping from a 52‑week high of $4.29 to a 52‑week low of $0.70 by 26 August 2026.
- The company’s market cap stood at approximately $24.4 million as of the latest close on 26 August 2026.
- The bankruptcy filing was prompted by financial pressures and the need to streamline operations while pursuing a strategic exit of non‑core assets.
Company Background
BioXcel Therapeutics was founded in 2018 and listed on Nasdaq. It leverages artificial intelligence for drug identification and development in the neuroscience and immuno‑oncology sectors. The company has pursued a global customer base and aims to bring transformative medicines to market.
Summary
BioXcel’s Chapter 11 filing and agreement to sell its BXCL501 asset to Teva represent a significant restructuring step. The transaction reflects Teva’s targeted acquisition strategy and offers a potential exit pathway for BioXcel’s investors in the context of the company’s ongoing bankruptcy proceedings.
